Publikationen, an denen er mitarbeitet Mar Tormo Díaz (9)

2020

  1. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

    Leukemia, Vol. 34, Núm. 11, pp. 2925-2933

2015

  1. Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML

    American Journal of Clinical Pathology, Vol. 144, Núm. 3, pp. 484-492

  2. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

    Blood Cancer Journal, Vol. 5, pp. e352

  3. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

    Oncotarget, Vol. 6, Núm. 31, pp. 31613-31627

2014

  1. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia

    Leukemia

2013

  1. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

    Leukemia, Vol. 27, Núm. 11, pp. 2157-2164

2010

  1. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group

    Haematologica, Vol. 95, Núm. 4, pp. 589-596

2009

  1. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

    Leukemia, Vol. 23, Núm. 3, pp. 486-491

2008

  1. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the programa Español de tratamiento en hematología pediatric-based protocol ALL-96

    Journal of Clinical Oncology, Vol. 26, Núm. 11, pp. 1843-1849